Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

This study is testing a new drug called U16 in patients with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to at least two prior treatments. U16 targets CD20, a protein on the surface of cancer cells. **You may be eligible if...** - You are between 18 and 70 years old - You have CD20-positive B-cell non-Hodgkin's lymphoma (including diffuse large B-cell lymphoma and related subtypes), confirmed by tissue testing - You have already received at least 2 prior lines of treatment, including chemotherapy containing anthracyclines, and CD20-targeting therapy - You have measurable disease on scans **You may NOT be eligible if...** - You have not had at least 2 prior lines of treatment - Your lymphoma is not CD20-positive - You are in poor overall health Talk to your doctor to see if this trial is right for you.